尚靖
个性化签名
- 姓名:尚靖
- 目前身份:
- 担任导师情况:
- 学位:
-
学术头衔:
博士生导师, 教育部“新世纪优秀人才支持计划”入选者
- 职称:-
-
学科领域:
岩土力学
- 研究兴趣:
尚靖 女,博士,教授, 1989 年毕业于兰州大学生物化学专业, 1999 年毕业于新疆大学药物资源专业, 2002 年 毕业于德国柏林自由大学分子生物学专业,理学博士。曾任新疆维吾尔自治区临床药学研究所副所长,新疆自治区人民医院医学研究中心主任。新疆药学会的常务理事,学术编辑委员会主任委员和国家自然基金的评委。 现就职于中国药科大学新药筛选中心, 任中国药科大学新药筛选中心副主任。曾被评为新疆自治区卫生系统“十佳青年”。 2004 年获新疆维吾尔自治区人民政府颁发的青年科技人员最高荣誉奖:自治区青年科技奖。2007年获评教育部“新世纪优秀人才”。
先后主持三项国家科技部重点项目(两项 863 专项),六项自治区科技重点项目。已在国内外核心刊物上发表学术论文 26 余篇。申请专利 2 项,累积经费达 380 万。在研究领域获得省部级科技进步二等奖三项,主持完成了多项产品开发;主持完成 3 个中药、天然药 5 类的创新药临床前研究。完成是新疆历史上第一个民族创新制剂的研究。在理论研究方面进行对疑难病白癜风药物筛选系统模型的研究和探讨,为治疗色素疾病药物筛选和色素毒性的评价提供了很好的应用模型。在色素疾病的研究及药物开发方面居于国内领先水平。另曾任 “新疆药用植物分离纯化实验室” 新疆自治区重点实验室培育基地主任,旨在对新疆特有的民族药用资源进行高水准研究,为新疆的药用资源开发提供坚实的物质理论基础。主持开发了“新药研发资料管理软件”,实现课题资料管理并应用到 863 课题的管理中,受到 863 专家组的好评。
-
主页访问
1478
-
关注数
0
-
成果阅读
133
-
成果数
3
【期刊论文】Isoliquiritigenin induces monocytic differentiation of HL-60 cells
尚靖, Defang Li a, , Zhenhua Wang a, Hongmei Chen a, Jingying Wang b, Qiusheng Zheng a, *, Jing Shang c, Ji Li a, b
Free Radical Biology & Medicine 46(2009)731-736,-0001,():
-1年11月30日
It has been proven that isoliquiritigenin could inhibit the proliferation of some kinds of cancer cell lines andhas a strong antioxidative activity. The purpose of this study is to investigate whether the antioxidantisoliquiritigenin affects the proliferation and redifferentiation in HL-60 cells. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) colorimetric method and trypan blue staining were used to measure cellproliferentiation and survival. The morphological changes, nitroblue tetrazolium chloride (NBT) reductiveactivity, and the CD11b and CD14 surface antigens were used as the biomarkers of redifferentiation of HL-60cells. The intracellular reactive oxygen species (iROS) level was detected by a fluorescent probe, 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA). Isoliquiritigenin (ISL) inhibited the cell proliferation anddecreased the iROS levels in a dose-dependent manner, while the treatment did not increase the lethalityrate. After 72 h treatment with 10μg/ml ISL, a typical differentiated morphology was observed in HL-60 cells,including the decrease of karyoplasmic ratio and the increase of kidney-shape nuclear cells. The positive rate(%) of CD11b (26.4±3.90 vs 7.70±1.04, Pb0.01) and CD14 (20.4±2.30 vs 2.63±0.133, Pb0.01) cells increasedsignificantly. The NBT reductive activity increased 2.3-fold as compared to that of the control group. As anantioxidant, ISL decreased the iROS formation in a dose-dependent manner. All the results indicate that theantioxidant ISL is able to induce the monocytic differentiation in leukemia cells. ISL has the potential as adrug to cure leukemia with fewer side effects.
Isoliquiritigenin HL-60 cells Differentiation Antioxidant
-
51浏览
-
0点赞
-
0收藏
-
0分享
-
207下载
-
0评论
-
引用
尚靖, Xin Cao a, b, e, Qi-Dong You a, *, Zhi-Yu Li a, Xiao-Rong Liu a, Dan Xu a, Qing-Long Guo a, Jing Shang c, Ji-Wang Chern d, Meng-Ling Chen d
Bioorganic & Medicinal Chemistry Letters 18(2008)6206-6209,-0001,():
-1年11月30日
Because both c-Src and iNOS are key regulatory enzymes in tumorigenesis, a new series of 4-heterocycleamine-3-quinolinecarbonitriles as potent dual inhibitors of both enzymes were designed, synthesizedand evaluated as multiple targets agents in cancer therapy. All compounds were evaluated by two relatedenzyme inhibition assays and an anti-proliferation assay in vitro. The results showed that most compoundsinhibited c-Src and iNOS well. The best compound 8 inhibited both enzymes with the IC50 valuesof 34.8 nM and 26.7 lM. Several compounds also showed moderate anti-proliferation at 10 lM againstcolon and liver cancer cell lines.
-
43浏览
-
0点赞
-
0收藏
-
0分享
-
102下载
-
0评论
-
引用
尚靖, Xin Cao, a Qi-Dong You, a, * Zhi-Yu Li, a Qing-Long Guo, a Jing Shang, bMing Yan, b Ji-Wang Chernc and Men-Ling Chenc
Bioorganic & Medicinal Chemistry 16(2008)5890-5898,-0001,():
-1年11月30日
Because both c-Src and iNOS are key regulatory enzymes in tumorigenesis, a new series of 4-heteroarylamino-3-quinolinecarbonitriles as potent dual inhibitors of both enzymes were designed, prepared, and evaluated for blocking multiple signaling pathways in cancer therapy. All compounds were evaluated by two related enzyme inhibition assays and an anti-proliferation assay in vitro. The results showed that most compounds could inhibit both enzymes, and several of them showed potent inhibition activity against different cancer cell lines. The best compound 20 (CPU-Y020) showed the IC50 values of 6.58 and 7.61 lM toward colon cancer HT-29 and liver cancer HepG2 cell lines.
-
39浏览
-
0点赞
-
0收藏
-
0分享
-
111下载
-
0评论
-
引用